Glucose Kabipac Fresenius Kabi (Glucose Monohydrate)

Glucose Kabipac is indicated for several clinical situations where an immediate source of glucose is required.

• Treatment of acute hypoglycemia in patients unable to take oral glucose, providing rapid elevation of blood glucose levels.
• Inclusion as a carbohydrate source in total parenteral nutrition (TPN) formulations to deliver calibrated caloric energy.
• Use in intravenous fluid and electrolyte replacement solutions to help maintain intravascular volume and osmolar balance.
• Support of patients during peri‑operative fasting, prolonged starvation, or severe catabolic states where oral intake is restricted.
• Management of metabolic conditions such as insulinoma or adrenal insufficiency that require controlled glucose infusion.

Glucose Kabipac may be associated with infusion‑related reactions and metabolic changes; reported events are categorized as common or serious.

Common

• Transient rise in blood glucose levels during or shortly after the infusion.
• Local irritation, erythema, or mild discomfort at the IV site.
• Small electrolyte shifts, such as modest changes in serum potassium or sodium.
• Headache, flushing, or a feeling of warmth during administration.

Serious

• Severe hyperglycemia that may lead to osmotic diuresis or ketoacidosis in susceptible individuals.
• Immediate hypersensitivity reactions, including rash, urticaria, bronchospasm, or anaphylaxis.
• Fluid overload or pulmonary edema, especially in patients with cardiac or renal impairment.
• Metabolic acidosis due to rapid glucose metabolism and lactate buildup.

When using Glucose Kabipac, clinicians should observe specific precautions to minimize risks and ensure safe administration.

• Verify patient’s blood glucose level before initiating therapy to avoid excessive hyperglycemia.
• Adjust infusion rate in patients with renal or cardiac insufficiency to prevent fluid overload.
• Monitor electrolytes, especially potassium and sodium, during prolonged or high‑dose infusions.
• Use aseptic technique and inspect the solution for particulate matter or discoloration before administration.
• Consider contraindications such as known hypersensitivity to glucose solutions or severe hyperglycemia.
• Document total carbohydrate intake when the product is part of a total parenteral nutrition regimen.

Glucose Kabipac can interact with other intravenous agents or affect metabolic control; awareness of potential interactions helps guide safe co‑administration.

Avoid

• Co‑administration with high‑dose insulin infusions without close glucose monitoring, which may precipitate severe hypoglycemia.
• Simultaneous infusion of hyperosmolar solutions that could increase the risk of fluid overload.

Use with caution

• Concurrent use of potassium‑containing IV fluids, as rapid glucose infusion may shift potassium intracellularly.
• Administration alongside diuretics that affect fluid balance, requiring careful monitoring of volume status.
• Use with catecholamine vasopressors, which can alter glucose metabolism and mask hyperglycemia.
• Co‑infusion with sodium bicarbonate solutions may affect acid‑base balance and should be monitored.